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Corrigendum
Corrigendum  to  “MHV-68  producing  mIFN1 is  severely  attenuated  in  vivo  and
effectively  protects  mice  against  challenge  with  wt  MHV-68”
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Eleonora  Aricòa,∗, Domenica  M.  Monquea, Giuseppina  D’Agostinoa, Federica  Moschellaa,
Massimo  Venditti a, Ulrich  Kalinkeb,  Deborah  J.  Allenc, James  P.  Stewartd, Anthony  A.  Nashc,
Filippo  Belardelli a, Maria  Ferrantinia
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The authors would like to rectify an error that occurred in their article.
James P. Stewart was mistakenly omitted from the published list of authors. His details have now been added.
The authors apologize for any inconvenience caused.
DOI of original article: 10.1016/j.vaccine.2011.03.092.
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